Gujarat Themis completes ₹1,200 crore acquisition of MicroBiopharm
pre-market1 source ↓written by the desknot a recommendation
Gujarat Themis Biosyn Limited has successfully completed the acquisition of 100% equity in Japan's MicroBiopharm for JPY 21.5 billion (approximately ₹1,200 crore). This move aims to enhance GTBL's capabilities as a globally integrated CDMO focused on fermentation and biotechnology-based manufacturing. The deal was funded through a blend of debt and equity, expected to be EPS accretive for the company.
Not investment advice. For informational purposes only.